PL4397376T3 - Kombinacja zawierająca inhibitor mek i inhibitor b-raf - Google Patents
Kombinacja zawierająca inhibitor mek i inhibitor b-rafInfo
- Publication number
- PL4397376T3 PL4397376T3 PL24175377.1T PL24175377T PL4397376T3 PL 4397376 T3 PL4397376 T3 PL 4397376T3 PL 24175377 T PL24175377 T PL 24175377T PL 4397376 T3 PL4397376 T3 PL 4397376T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitor
- combination containing
- raf
- mek
- mek inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25221309P | 2009-10-16 | 2009-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4397376T3 true PL4397376T3 (pl) | 2026-03-30 |
Family
ID=43876568
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19174594.2T PL3560498T3 (pl) | 2009-10-16 | 2010-10-15 | Kombinacja zawierająca inhibitor mek i inhibitor b-raf |
| PL24175377.1T PL4397376T3 (pl) | 2009-10-16 | 2010-10-15 | Kombinacja zawierająca inhibitor mek i inhibitor b-raf |
| PL10824148T PL2488033T3 (pl) | 2009-10-16 | 2010-10-15 | Kombinacja zawierająca inhibitor MEK i inhibitor B-raf |
| PL22189749.9T PL4159217T3 (pl) | 2009-10-16 | 2010-10-15 | Kombinacja zawierająca inhibitor mek i inhibitor b-raf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19174594.2T PL3560498T3 (pl) | 2009-10-16 | 2010-10-15 | Kombinacja zawierająca inhibitor mek i inhibitor b-raf |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10824148T PL2488033T3 (pl) | 2009-10-16 | 2010-10-15 | Kombinacja zawierająca inhibitor MEK i inhibitor B-raf |
| PL22189749.9T PL4159217T3 (pl) | 2009-10-16 | 2010-10-15 | Kombinacja zawierająca inhibitor mek i inhibitor b-raf |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US8703781B2 (pl) |
| EP (5) | EP4397376B1 (pl) |
| JP (1) | JP5718929B2 (pl) |
| KR (1) | KR101729116B1 (pl) |
| CN (1) | CN102655753B (pl) |
| AU (1) | AU2010306653B2 (pl) |
| BR (1) | BR112012008854B8 (pl) |
| CA (1) | CA2775803C (pl) |
| CL (1) | CL2012000964A1 (pl) |
| CO (1) | CO6531498A2 (pl) |
| CR (1) | CR20120155A (pl) |
| CY (1) | CY1122013T1 (pl) |
| DK (4) | DK4397376T3 (pl) |
| DO (1) | DOP2012000091A (pl) |
| EA (1) | EA020589B1 (pl) |
| ES (4) | ES2930157T3 (pl) |
| FI (2) | FI4397376T3 (pl) |
| HR (3) | HRP20191617T1 (pl) |
| HU (3) | HUE060206T2 (pl) |
| IL (1) | IL219073A (pl) |
| LT (4) | LT4159217T (pl) |
| MA (1) | MA33746B1 (pl) |
| ME (1) | ME03497B (pl) |
| MX (1) | MX2012004413A (pl) |
| MY (1) | MY174759A (pl) |
| NZ (1) | NZ598913A (pl) |
| PE (1) | PE20121093A1 (pl) |
| PH (1) | PH12012500742A1 (pl) |
| PL (4) | PL3560498T3 (pl) |
| PT (4) | PT3560498T (pl) |
| RS (4) | RS65800B1 (pl) |
| SI (3) | SI4397376T1 (pl) |
| UA (1) | UA105064C2 (pl) |
| WO (1) | WO2011047238A1 (pl) |
| ZA (1) | ZA201202612B (pl) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| UA105005C2 (uk) | 2008-06-16 | 2014-04-10 | Юніверсіті Оф Теннессі Рісерч Фаундейшн | Сполуки для лікування раку |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| EP2545187B1 (en) * | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| WO2012061683A2 (en) * | 2010-11-05 | 2012-05-10 | Glaxosmithkline Llc | Methods for treating cancer |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| WO2013087914A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
| EP2793938A4 (en) * | 2011-12-22 | 2015-07-22 | Glaxosmithkline Llc | METHOD OF TREATING CANCER USING A MAGE-A3 IMMUNOTHERAPEUTIC PRODUCT COMPRISING A BRAF INHIBITOR AND / OR MEK INHIBITOR |
| WO2013144923A1 (en) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| CN104582706A (zh) * | 2012-09-04 | 2015-04-29 | 葛兰素史克有限责任公司 | 辅助癌症治疗的方法 |
| JP2016503399A (ja) * | 2012-10-25 | 2016-02-04 | ノバルティス アーゲー | 組合せ |
| PE20151024A1 (es) * | 2012-11-30 | 2015-07-27 | Glaxosmithkline Llc | Composicion farmaceutica novedosa |
| CN103965170A (zh) * | 2013-01-24 | 2014-08-06 | 通化济达医药有限公司 | 苯磺酰胺吡唑激酶抑制剂 |
| CN105163584B (zh) | 2013-03-05 | 2019-06-04 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| AU2014276440A1 (en) * | 2013-06-03 | 2015-11-05 | Novartis Ag | Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor |
| CN104540822B (zh) * | 2013-07-08 | 2016-08-31 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的晶型及其制备方法 |
| WO2015059677A1 (en) * | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
| CN103588767B (zh) * | 2013-11-20 | 2016-01-20 | 苏州明锐医药科技有限公司 | 达拉菲尼的制备方法 |
| BR112016011222A2 (pt) * | 2013-12-12 | 2017-09-19 | Novartis Ag | Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer |
| CN111534580B (zh) | 2013-12-28 | 2024-06-04 | 夸登特健康公司 | 用于检测遗传变异的方法和系统 |
| WO2015105822A1 (en) * | 2014-01-07 | 2015-07-16 | Glaxosmithkline Llc | Cancer treatment method |
| AU2015256208B2 (en) | 2014-05-06 | 2020-01-02 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| KR101629184B1 (ko) | 2014-12-10 | 2016-06-13 | 현대오트론 주식회사 | Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법 |
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| CA3042697A1 (en) * | 2016-11-03 | 2018-05-11 | The Regents Of The University Of Michigan | Small molecule dual inhibitors of egfr/pi3k and uses thereof |
| CN112867803A (zh) | 2018-10-16 | 2021-05-28 | 诺华股份有限公司 | 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| TW202118488A (zh) * | 2019-07-26 | 2021-05-16 | 大陸商蘇州亞盛藥業有限公司 | Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途 |
| CA3149796A1 (en) | 2019-08-02 | 2021-02-11 | Onehealthcompany, Inc. | Anti-cancer agents for the treatment of canine cancers |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CN114981298B (zh) * | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| US20230084515A1 (en) * | 2020-02-19 | 2023-03-16 | Vanderbilt University | Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy |
| EP4308935A1 (en) | 2021-03-18 | 2024-01-24 | Novartis AG | Biomarkers for cancer and methods of use thereof |
| JP2024542019A (ja) * | 2021-11-02 | 2024-11-13 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置する方法 |
| US20250032494A1 (en) | 2021-12-06 | 2025-01-30 | My Personal Therapeutics Ltd | A combination treatment for cancer |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| EP4788839A1 (en) | 2023-10-03 | 2026-08-12 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| CA2395564A1 (en) * | 1999-11-22 | 2001-05-31 | Smithkline Beecham Plc | Novel compounds |
| DE102004018198A1 (de) * | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 |
| WO2008120004A1 (en) * | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
| CA2694646C (en) * | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
-
2010
- 2010-10-15 HU HUE19174594A patent/HUE060206T2/hu unknown
- 2010-10-15 PT PT191745942T patent/PT3560498T/pt unknown
- 2010-10-15 LT LTEP22189749.9T patent/LT4159217T/lt unknown
- 2010-10-15 LT LTEP24175377.1T patent/LT4397376T/lt unknown
- 2010-10-15 CA CA2775803A patent/CA2775803C/en active Active
- 2010-10-15 JP JP2012534386A patent/JP5718929B2/ja active Active
- 2010-10-15 EP EP24175377.1A patent/EP4397376B1/en active Active
- 2010-10-15 SI SI201032168T patent/SI4397376T1/sl unknown
- 2010-10-15 FI FIEP24175377.1T patent/FI4397376T3/fi active
- 2010-10-15 DK DK24175377.1T patent/DK4397376T3/da active
- 2010-10-15 PT PT221897499T patent/PT4159217T/pt unknown
- 2010-10-15 EA EA201290149A patent/EA020589B1/ru not_active IP Right Cessation
- 2010-10-15 HR HRP20191617 patent/HRP20191617T1/hr unknown
- 2010-10-15 MX MX2012004413A patent/MX2012004413A/es active IP Right Grant
- 2010-10-15 DK DK19174594.2T patent/DK3560498T3/da active
- 2010-10-15 PT PT241753771T patent/PT4397376T/pt unknown
- 2010-10-15 FI FIEP22189749.9T patent/FI4159217T3/fi active
- 2010-10-15 EP EP10824148.0A patent/EP2488033B1/en active Active
- 2010-10-15 RS RS20240873A patent/RS65800B1/sr unknown
- 2010-10-15 MY MYPI2012001680A patent/MY174759A/en unknown
- 2010-10-15 ES ES19174594T patent/ES2930157T3/es active Active
- 2010-10-15 PL PL19174594.2T patent/PL3560498T3/pl unknown
- 2010-10-15 HR HRP20260236TT patent/HRP20260236T1/hr unknown
- 2010-10-15 DK DK22189749.9T patent/DK4159217T3/da active
- 2010-10-15 NZ NZ598913A patent/NZ598913A/xx unknown
- 2010-10-15 DK DK10824148.0T patent/DK2488033T3/da active
- 2010-10-15 SI SI201031933T patent/SI2488033T1/sl unknown
- 2010-10-15 PL PL24175377.1T patent/PL4397376T3/pl unknown
- 2010-10-15 LT LTEP10824148.0T patent/LT2488033T/lt unknown
- 2010-10-15 ES ES10824148T patent/ES2745479T3/es active Active
- 2010-10-15 RS RS20260205A patent/RS67767B1/sr unknown
- 2010-10-15 PT PT10824148T patent/PT2488033T/pt unknown
- 2010-10-15 EP EP19174594.2A patent/EP3560498B1/en not_active Revoked
- 2010-10-15 BR BR112012008854A patent/BR112012008854B8/pt active IP Right Grant
- 2010-10-15 PL PL10824148T patent/PL2488033T3/pl unknown
- 2010-10-15 HU HUE10824148A patent/HUE046139T2/hu unknown
- 2010-10-15 EP EP25216764.8A patent/EP4706770A3/en active Pending
- 2010-10-15 LT LTEP19174594.2T patent/LT3560498T/lt unknown
- 2010-10-15 SI SI201032148T patent/SI4159217T1/sl unknown
- 2010-10-15 HR HRP20221304TT patent/HRP20221304T1/hr unknown
- 2010-10-15 AU AU2010306653A patent/AU2010306653B2/en active Active
- 2010-10-15 ES ES24175377T patent/ES3063926T3/es active Active
- 2010-10-15 UA UAA201204675A patent/UA105064C2/uk unknown
- 2010-10-15 HU HUE22189749A patent/HUE067723T2/hu unknown
- 2010-10-15 RS RSP20191095 patent/RS59181B1/sr unknown
- 2010-10-15 RS RS20220984A patent/RS63702B1/sr unknown
- 2010-10-15 EP EP22189749.9A patent/EP4159217B1/en not_active Revoked
- 2010-10-15 ME MEP-2019-236A patent/ME03497B/me unknown
- 2010-10-15 CN CN201080046640.6A patent/CN102655753B/zh active Active
- 2010-10-15 KR KR1020127012649A patent/KR101729116B1/ko active Active
- 2010-10-15 WO PCT/US2010/052808 patent/WO2011047238A1/en not_active Ceased
- 2010-10-15 PL PL22189749.9T patent/PL4159217T3/pl unknown
- 2010-10-15 ES ES22189749T patent/ES2986037T3/es active Active
- 2010-10-15 US US13/499,779 patent/US8703781B2/en active Active
- 2010-10-15 PE PE2012000502A patent/PE20121093A1/es active IP Right Grant
- 2010-10-15 PH PH1/2012/500742A patent/PH12012500742A1/en unknown
-
2012
- 2012-03-27 CR CR20120155A patent/CR20120155A/es unknown
- 2012-04-03 DO DO2012000091A patent/DOP2012000091A/es unknown
- 2012-04-05 IL IL219073A patent/IL219073A/en active IP Right Grant
- 2012-04-11 ZA ZA2012/02612A patent/ZA201202612B/en unknown
- 2012-04-16 CL CL2012000964A patent/CL2012000964A1/es unknown
- 2012-04-27 CO CO12069732A patent/CO6531498A2/es active IP Right Grant
- 2012-05-11 MA MA34863A patent/MA33746B1/fr unknown
-
2014
- 2014-03-05 US US14/197,421 patent/US8952018B2/en active Active
- 2014-12-22 US US14/578,804 patent/US20150111904A1/en not_active Abandoned
-
2019
- 2019-09-09 CY CY20191100943T patent/CY1122013T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2488033T3 (pl) | Kombinacja zawierająca inhibitor MEK i inhibitor B-raf | |
| NL300891I2 (nl) | Lotilaner en zouten daarvan | |
| PH12012500709A1 (en) | Combinations of a pi3k inhibitor and a mek inhibitor | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| BRPI0806898A2 (pt) | Inibidores de mek | |
| BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
| BRPI0908115A2 (pt) | torneira | |
| DK2432993T3 (da) | En vindmølle og fremgangsmåde | |
| EP2454164A4 (en) | HAHN | |
| DK2403764T3 (da) | Opbevaringsæske | |
| IT1391761B1 (it) | Rubinetto elettronico | |
| DK2310037T3 (da) | Conglutin-gamma as-medikament og -kosttilskudpatentkrav | |
| EP2309859A4 (en) | ENZYME HEMMER AND ITS USE | |
| TH105701B (th) | ตู้วางและเก็บของ | |
| TH104451B (th) | ตู้วางและเก็บของ | |
| TH0901002502A (th) | สารรวมของยาซึ่งประกอบรวมด้วยตัวยับยั้ง dgat และ ppar-แอกอนิสท์ | |
| TWI348092B (en) | Computer device and case thereof | |
| UA19888S (uk) | Логотип | |
| CN301140175S (zh) | 标贴 | |
| FI20096360A0 (fi) | Bioliima ja puulevy | |
| IL216594A0 (en) | Proteasome inhibitors and uses thereof | |
| UA21499S (uk) | Інформаційно-рекламний щит | |
| UA21256S (uk) | Рекламно-інформаційне табло | |
| UA19844S (uk) | Етикетка |